

Curriculum Vitae

Personal information Erica Brivio

Work experience

CURRENT POSITION

Consultant Pediatric Onco-hematologist

- Clinical activity in the hemato-oncology department and transplant unit
- Research physician in the Early Clinical Trial Unit - Phase I-II studies in pediatric leukemia

Princess Maxima Centre for Pediatric Oncology, Utrecht, The Netherlands

Previous appointments

June - Dec 2023 Placement at EMA (European Medicines Agency) as a collaborating expert, within the Aladdin Educational programme of the ACCELERATE

20019-2023 PhD "Phase I-II first in child registrational studies in pediatric leukemia " – Erasmus MC

2013-2018 Residency in Pediatrics University of Milano Bicocca (Italy)

June 2017-Nov 2017 Erasmus traineeship/research physician Phase I-II clinical trials in pediatric hematology-oncology , Erasmus MC, Rotterdam, The Netherlands - Prof. C.M. Zwaan

Aug 2010-Oct 2010 Outreach Program Internship Pediatric Haematology-oncology – Hospital Infantil La Mascota, Managua, Nicaragua

Education and training

2012 Medical Degree, maximum cum laude, University of Milano Bicocca (Italy)

2018 Specialist in Pediatrics, University of Milano Bicocca (Italy)

2023 PhD Early phase clinical trials in pediatric leukemia, Erasmus University, Rotterdam (The Netherlands)

Additional information

Publications

PUBLICATIONS

1. Brivio E, Karres D, Lesa G, Ligas F. *Approved medicines for paediatric solid tumours in Europe: Lessons from the life cycle of a paediatric investigation plan*. EJC Paediatric Oncology, 2024 Volume 4, 100190
2. Brivio E*, Pennesi E*, Willemse ME, Huitema ADR, Jiang Y, van Tinteren H, van der Velden VHJ, Beverloo BH, den Boer ML, Rammeloo LAJ, Hudson C, Heerema N, Kowalski K, Zhao H, Kuttischreuter L, Bautista Sirvent FJ, Bukowinski A, Rizzari C, Pollard J, Murillo-Sanjuán L, Kutny M, Zarnegar-Lumley S, Redell M, Cooper S, Bertrand Y, Petit A, Krystal J, Metzler M, Lancaster D, Bourquin JP, Motwani J, van der Sluis IM, Locatelli F, Roth ME, Hijiya N, Zwaan CM. *Bosutinib in Resistant and Intolerant Pediatric Patients with Chronic Phase Chronic Myeloid Leukemia: Results from the Phase I Part of Study ITCC054/COG AAML1921*. J Clin Oncol. 2023 Nov 30;JCO2300897. * contributed equally
3. Brivio E, Locatelli F, Lopez-Yurda M, Malone A, Díaz-de-Heredia C, Bielora B, Rossig C, van der Velden VHJ, Ammerlaan ACJ, Thanos A, van der Sluis IM, den Boer ML, Chen Y, Sleight B, Brethon B, Nysom K, Šrámková L, Øra, Vinti L, Chen-Santel C, Zwaan CM. *A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study)* Blood. 2021 Mar 25;137(12):1582-1590.
4. Brivio E, Bautista F, Zwaan CM *Naked antibodies and antibody-drug conjugates: targeted therapy for childhood acute lymphoblastic leukemia*. Haematologica. 2024 Jun 1;109(6):1700-1712
5. Brivio E, Baruchel A, Beishuizen A, Bourquin JP, Brown PA, Cooper T, Gore L, Kolb EA, Locatelli F, Maude SL, Mussai FJ, Vormoor-Bürger B, Vormoor J, von Stackelberg A, Zwaan CM *Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphoma*. Eur J Cancer. 2022 Mar;164:1-17.
6. Ilan U*, Brivio E*, Algeri M, Balducci A, Gonzalez-Vincent M, Locatelli F, Zwaan CM, Baruchel A, Lindemans C, Bautista F. *The Development of New Agents for Post-Hematopoietic Stem Cell Transplantation Non-Infectious Complications in Children*. J Clin Med. 2023 Mar 9;12(6):2149. * contributed equally
7. Ceolin V*, Brivio E*, van Tinteren H, Rheingold SR, Leahy A, Vormoor B, O'Brien MM, Rubinstein JD, Kalwak K, De Moerloose B, Jacoby E, Bader P, López-Duarte M, Goemans BF, Locatelli F, Hoogerbrugge P, Calkoen FG, Zwaan CM *Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia*. Leukemia 37, 53–60 2023. * contributed equally
8. Pennesi E, Brivio E, Ammerlaan ACJ, Jiang Y, Van der Velden VHJ, Beverloo HB, Sleight B, Locatelli F, Brethon B, Rossig C, Engstler G, Nilsson A, Bruno B, Petit A, Bielora B, Rizzari C, Rialland F, Rubio-San-Simón A, Sirvent FJB, Díaz-de-Heredia C, Rives S, Zwaan CM. *Inotuzumab ozogamicin combined with chemotherapy in pediatric B-cell precursor CD22+ acute lymphoblastic leukemia: results of the phase IB ITCC-059 trial*. Haematologica. 2024 Oct 1;109(10):3157-3166.
9. Brivio E, Chantraine CF, Gruber TA, Thanos A, Rialland-Battisti F, Contet A, Elitzur S, Dalla-Pozza L, Kállay KM, Li CK, Kato M, Markova I, Schmiegelow K, Bodmer N, Breese EH, Hoogendijk R, Pieters R, Zwaan CM. *Inotuzumab Ozogamicin in Infants and Young Children with Relapsed or Refractory Acute Lymphoblastic*

- Leukemia: a case series.* Br J Haematol. 2021 Jun;193(6):1172-1177
10. Pennesi E, Michels N, Brivio E, van der Velden VHJ, Jiang Y, Thano A, Ammerlaan AJC, Boer JM, Beverloo HB, Sleight B, Chen Y, Vormoor-Bürger B, Rives S, Bieloraí B, Rössig C, Petit A, Rizzari C, Engstler G, Stary J, Bautista Sirvent FJ, Chen-Santel C, Bruno B, Bertrand Y, Rialland F, Plat G, Reinhardt D, Vinti L, Von Stackelberg A, Locatelli F, Zwaan CM *Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial.* Leukemia. 2022 Jun;36(6):1516-1524.
 11. Pearson ADJ, Zwaan CM, Kolb EA, Karres D, Guillot J, Kim SY, Marshall L, Tasian SK, Smith M, Cooper T, Adamson PC, Barry E, Benettaib B, Binlich F, Borgman A, Brivio E, Capdeville R, Delgado D, et al *Paediatric Strategy Forum for Medicinal Product Development for Acute Myeloid Leukaemia in Children and Adolescents.* European Journal of Cancer 136 (2020) 116-129
 12. Wu JH, Pennesi E, Bautista F, Garrett M, Fukuhara K, Brivio E, Ammerlaan ACJ, Locatelli F, van der Sluis IM, Rossig C, Chen-Santel C, Bieloraí B, Petit A, Stary J, Díaz-de-Heredia C, Rives S, O'Maricaigh A, Rizzari C, Engstler G, Nysom K, Rubio-San-Simón A, Bruno B, Bertrand Y, Brethon B, Rialland F, Plat G, Dirksen U, Sramkova L, Zwaan CM, Huitema ADR. *Population Pharmacokinetics of Inotuzumab Ozogamicin in Pediatric Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Results of Study ITCC-059.* Clin Pharmacokinet. 2024 Jul;63(7):981-997.
 13. Brivio E, Cossio A, Borra D, Silvestri D, Prunotto G, Colombini A, Verna M, Rizzari C, Biondi A, Conter V, Valsecchi MG, Balduzzi A *Osteonecrosis in pediatric acute lymphoblastic leukemia: incidence, risk factors, radiological patterns and evolution in a single-center cohort.* Br J Haematol. 2022 Jun;197(5):602-608
 14. Brivio E, Zwaan M.C. ALK inhibition in two emblematic cases of pediatric inflammatory myofibroblastic tumor: efficacy and side effects. *Pediatr Blood Cancer.* 2019;66:e27645.
 15. Navarrete M, Rossi E, Brivio E, Carrillo JM, Bonilla M, Vasquez R, Peña A, Fu L, Martinez R, Espinoza CM, Lacayo LF, Rodriguez H, Batista R, Barr R, Howard SC, Ribeiro RC, Masera G, Biondi A, Conter V, Valsecchi MG. *Treatment of childhood acute lymphoblastic leukemia in central America: A lower-middle income countries experience.* *Pediatr Blood Cancer.* 2014 May;61(5):803

Projects

RESEARCH EXPERIENCES

- **Investigator/Sponsor tasks in Phase I-II first in child registration studies:**

1. Phase I/II study of Inotuzumab Ozogamicin (ITCC-059) as a single agent and in combination with chemotherapy in R/R ALL
2. Phase I/II study of Bosutinib in CML (ITCC-054/AAML1621)

Writing substantial amendments (i.e. new cohorts inclusion, as InO in combination with chemotherapy)

- Writing response to European EC/CA after submission of substantial amendments
- Preparing and presenting data during investigators meetings
- Supporting local investigators and study answering protocol and treatment related questions
- Working with the statistician on the study analysis (preparation of the study report and publication of data)
- Presenting results in international meeting

3. Phase I/II study of Vyxeos in combination with Clofarabine in R/R AML patients (ITCC-092)

- Designing the study and writing the protocol (implemented at the EORTC course 2019)
- Research grant obtained from Jazz Pharmaceuticals (225 keuro) to implement the study proposal
- Designing CRFs
- Writing patients' information sheet
- Following the process for opening sites

- Co-promotor PhD student Edoardo Pennesi, Early stage drug development studies in pediatric leukemia, Erasmus University, promotor Prof. C.M. Zwaan
- Sub-investigator in early clinical trials in pediatric hematology-oncology

Memberships

International Boards/Committees

2021 onwards: HEMA-committee of ITCC (Innovative therapies in Children with Cancer) early career investigator

Other Relevant Information

CERTIFICATES

14.04.2023	IPOLS – Pediatric oncology life support training
28.02.2024	Basic course for clinical investigators (BROK®)
15-21.06.2019	EORTC/ESMO/ECCO/AACR workshop Methods in clinical cancer research,
Oct 2018	ITCC drug development training days, Utrecht, the Netherlands
06.02.2018	ICH-GCP certificate